• br Conflict of interest br Supplementary methods and materia

  2021-04-02

  

  Conflict of interest Supplementary methods and materials Acknowledgments This work was supported by an Early Career Researcher grant awarded by the Institute of Health and Biomedical Innovation to IMW and Queensland University of Technology, and grants awarded to SS by the Prostate Cancer F

• br Structure and function of EPAC isoforms EPACs are guanine

  2021-04-02

  

  Structure and function of EPAC isoforms EPACs are guanine nucleotide exchange factors (GEFs) for the Ras-like GTPases Rap1 and Rap2 [9]. There are two mammalian EPAC isoforms, EPAC1 and EPAC2 1, 2 (Figure 1). Whereas EPAC1 displays a wide tissue distribution, the expression of EPAC2 is more restr

• While we previously demonstrated that TraG

  2021-04-02

  

  While we previously demonstrated that TraG is inhibited by specific transglycosylase inhibitors and that enzymatic activity is strongly reduced upon mutation of the potential catalytic core (Arends et al., 2013), the enzymatic mechanism of both domains was not assigned. Here, by mass spectrometry an

• br Conflicts of interest br

  2021-04-02

  

  Conflicts of interest Financial support NZ is an Established Investigator of the Dutch Heart Foundation (2013T111) and is supported by an ERC Consolidator grant (617376) from the European Research Council and by a Vici grant from the Netherlands Organization for Scientific Research (NWO; 91818

• Z-YVAD-FMK br Discussion Previous studies have reported conf

  2021-04-02

  

  Discussion Previous studies have reported conflicting association results between the functional variant DBH −1021C>T and PD [8], [9]. Our findings would suggest that DBH −1021C>T does not dramatically decrease the risk of disease although it may marginally affect symptomatic AAO. However, whethe

• The field of synthetic cytokine biology continues to grow

  2021-04-02

  

  The field of synthetic cytokine biology continues to grow through molecular, physiological and pathophysiological insights, as well as via new methodical advances. The approval of chimeric antigen receptor (CAR) T cell immunotherapy by the US Food and Drug administration (FDA) in August 2017 for rel

• To ascertain that the slower migrating bands represented pho

  2021-04-02

  

  To ascertain that the slower migrating bands represented phosphorylated CDK5, we performed a phosphatase assay. Lysates of lcz696 receptor co-expressing p35 and either WT or D144N CDK5 were immunoprecipitated using an anti-p35 antibody. The immunoprecipitates were then dephosphorylated using SAP al

• The present review also summarizes the

  2021-04-02

  

  The present review also summarizes the efforts that have been made to find new c-FMS inhibitors under clinical trial as given in the Table 1. These inhibitors may reduce the burdens of potency and side effects that have faced the scientists globally. ABT-869 41 was manufactured in Abbott laboratorie

• The corticotropin releasing factor CRF

  2021-04-02

  

  The corticotropin-releasing factor (CRF) also referred to as corticotropin-releasing hormone, is a key mediator of mammalian endocrine, behavioral, autonomic, and immune responses to stress (Vale et al., 1981, Owens and Nemeroff, 1991, Bale and Vale, 2004). Within the hypothalamic–pituitary–adrenal

• br Acknowledgments br Introduction Cell cycle arrest or dela

  2021-04-01

  

  Acknowledgments Introduction Cell cycle arrest or delay may occur at 3 major checkpoints, i.e. G1/S, intra-S and G2/M. p53 has a central role in controlling the G1/S checkpoint, and its loss or deactivation, occurring in the majority of cancers, forces cancer cells to rely on the S and G2/M ch

• Previously we have shown that

  2021-04-01

  

  Previously, we have shown that the overexpression of ERRγ induces exercise-like oxidative muscle remodeling without engaging changes in the expression level or activity of PGC1α (Narkar et al., 2011). In this study, overexpression of ERRγ in PKO muscle reveals that ERRγ-activated target genes can ac

• Primary renal PNET was first reported by Seemayer et al

  2021-04-01

  

  Primary renal PNET was first reported by Seemayer et al in 1975. The possible etiology of rPNET is based on the theory of neural cell intussusception in the kidney during development that initiates the tumorigenesis. rPNET most commonly affects young adults, with a mean age of 30.4 years and male pr

• br Ultrasonic pretreatment of substrates Substrate pretreatm

  2021-04-01

  

  Ultrasonic pretreatment of substrates Substrate pretreatment is widely used in the biofuel, textile and food industries since the substrates are always difficult to degrade. During some enzymatic hydrolysis reactions, the protective layer of the substrate impedes the reaction. Ultrasonic treatme

• br Are incretins the only mediators of the anti

  2021-04-01

  

  Are incretins the only mediators of the anti-hyperglycaemic effects of DPP-4 inhibitors? Even though both GLP-1 and GIP were identified as substrates for DPP-4 early on [17], [19], [20], [22], and DPP-4 inhibition in vivo raises levels of the intact endogenous forms of both of them [43], [44], fr

• Henderson et al reported that

  2021-03-31

  

  Henderson et al. [20] reported that allergen-induced airway remodeling was blocked by the CysLT1 receptor antagonist montelukast. The development of epithelial thickening and mucus accumulation at relatively small 6-Chloromelatonin was also suppressed by montelukast. The CysLT2 receptor antagonist

14376 records 643/959 page Previous Next First page 上5页 641642643644645 下5页 Last page